title: Hyperlipidemia does not prevent the cardioprotection by postconditioning against myocardial ischemia/reperfusion injury and the involvement of hypoxia inducible factor-1alpha upregulation.
abstract: Hyperlipidemia is regarded as an independent risk factor in the development of ischemic heart disease, and it can increase the myocardial susceptibility to ischemia/reperfusion (I/R) injury. Ischemic postconditioning (Postcon) has been demonstrated to attenuate the myocardial injury induced by I/R in normal conditions. But the effect of ischemic Postcon on hyperlipidemic animals is unknown. Hypoxia inducible factor-1 (HIF-1) has been demonstrated to play a central role in the cardioprotection by preconditioning, which is one of the protective strategies except for Postcon. The aim of this study was to determine whether Postcon could reduce myocardial injury in hyperlipidemic animals and to assess whether HIF-1 was involved in Postcon mechanisms. Male Wistar rats underwent the left anterior descending coronary occlusion for 30 min followed by 180 min of reperfusion with or without Postcon after fed with high fat diet or normal diet for 8 weeks. The detrimental indices induced by the I/R insult included infarct size, plasma creatine kinase activity and caspase-3 activity. Results showed that hyperlipidemia remarkably enhanced the myocardial injury induced by I/R, while Postcon significantly decreased the myocardial injury in both normolipidemic and hyperlipidemic rats. Moreover, both hyperlipidemia and I/R promoted the HIF-1alpha expression. Most importantly, we have for the first time demonstrated that Postcon further induced a significant increase in HIF-1alpha protein level not only in normolipidemic but also in hyperlipidemic conditions. Thus, Postcon reduces the myocardial injury induced by I/R in normal and hyperlipidemic animals, and HIF-1alpha upregulation may involve in the Postcon-mediated cardioprotective mechanisms.
authors.affiliation: Department of Physiology, Shanxi Medical University, Taiyuan 030001, China.
authors.forename: Huanxin
authors.initials: H
authors.lastname: Zhao
authors.forename: Yehong
authors.initials: Y
authors.lastname: Wang
authors.forename: Ye
authors.initials: Y
authors.lastname: Wu
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Li
authors.forename: Guangzhao
authors.initials: G
authors.lastname: Yang
authors.forename: Xiurui
authors.initials: X
authors.lastname: Ma
authors.forename: Rongrui
authors.initials: R
authors.lastname: Zhao
authors.forename: Huirong
authors.initials: H
authors.lastname: Liu
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents; D006949:Hyperlipidemias / Q000150:complications / Q000378:metabolism* / Q000628:therapy*; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism*; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D008297:Male; D015425:Myocardial Reperfusion / Q000379:methods*; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome
chemical_list: D002316:Cardiotonic Agents; C497444:Hif1a protein, rat; D051795:Hypoxia-Inducible Factor 1, alpha Subunit